The risk factors for thromboembolism caused by Mycoplasma pneumoniae infection include severe Mycoplasma pneumoniae pneumonia，elevated D-dimer levels，abnormal inflammatory markers，platelet abnormalities，lung consolidation，lung necrosis and pleural effusion，and so on.In terms of treatment，tetracycline and quinolone antibiotics have shown new advantages in addressing the recent prevalence of macrolide resistant mycoplasma.Regarding anticoagulant therapy，direct oral anticoagulants represented by rivaroxaban have significant advantages and are safe in children's medication.In addition，the application of traditional Chinese medicine for promoting blood circulation and removing blood stasis needs to be developed.The identification and intervention of risk factors related to coagulation disorders and thromboembolism caused by Mycoplasma pneumoniae infection can help improve treatment effectiveness.

The risk factors for thromboembolism caused by Mycoplasma pneumoniae infection include severe Mycoplasma pneumoniae pneumonia，elevated D-dimer levels，abnormal inflammatory markers，platelet abnormalities，lung consolidation，lung necrosis and pleural effusion，and so on.In terms of treatment，tetracycline and quinolone antibiotics have shown new advantages in addressing the recent prevalence of macrolide resistant mycoplasma.Regarding anticoagulant therapy，direct oral anticoagulants represented by rivaroxaban have significant advantages and are safe in children's medication.In addition，the application of traditional Chinese medicine for promoting blood circulation and removing blood stasis needs to be developed.The identification and intervention of risk factors related to coagulation disorders and thromboembolism caused by Mycoplasma pneumoniae infection can help improve treatment effectiveness.

A 30-year-old female patient received oral rifampicin 0.562 5 g (before breakfast) and isoniazid 0.4 g (after dinner) for pulmonary tuberculosis.There were no abnormalities in her blood routine and liver function indexes before medication.Three days after the medication,the patient developed fatigue,nausea,and vomiting.The next-day laboratory tests showed white blood cell count 1.1 × 109/L,neutrophil count 0.32 × 109/L,hemoglobin (Hb) 120 g/L,platelet count (PLT) 149 × 109/L,alanine aminotransferase (ALT) 368 U/L,aspartate aminotransferase (AST) 1 333 U/L,total bilirubin (TBil)19.7 μmol/L,and direct bilirubin (DBil) 6.6 μmol/L.Liver injury and neutropenia were diagnosed.Considering the reason from current medication,rifampicin and isoniazid were discontinued and liverprotective and symptomatic treatments were given.On day 4 of the withdrawal,the patient's symptoms improved and laboratory tests showed neutrophil count 1.50 × 109/L,ALT 163 U/L,AST 139 U/L,TBil 9.0 μmol/L,and DBil 3.7 μmol/L.On day 7 of the withdrawal,the patient's liver function improved (ALT 75 U/L,AST 33 U/L,TBil 6.4 μmol/L,and DBil 3.3 μmol/L) and her neutrophil count was 1.60 × 109/L.One week after discharge,the neutrophil count was 1.70 × 109/L;the levels of ALT,AST,TBil,and DBil were 30 U/L,34 U/L,10.0 μmol/L,and 4.2 μmol/L,respectively.

A 30-year-old female patient received oral rifampicin 0.562 5 g (before breakfast) and isoniazid 0.4 g (after dinner) for pulmonary tuberculosis.There were no abnormalities in her blood routine and liver function indexes before medication.Three days after the medication,the patient developed fatigue,nausea,and vomiting.The next-day laboratory tests showed white blood cell count 1.1 × 109/L,neutrophil count 0.32 × 109/L,hemoglobin (Hb) 120 g/L,platelet count (PLT) 149 × 109/L,alanine aminotransferase (ALT) 368 U/L,aspartate aminotransferase (AST) 1 333 U/L,total bilirubin (TBil)19.7 μmol/L,and direct bilirubin (DBil) 6.6 μmol/L.Liver injury and neutropenia were diagnosed.Considering the reason from current medication,rifampicin and isoniazid were discontinued and liverprotective and symptomatic treatments were given.On day 4 of the withdrawal,the patient's symptoms improved and laboratory tests showed neutrophil count 1.50 × 109/L,ALT 163 U/L,AST 139 U/L,TBil 9.0 μmol/L,and DBil 3.7 μmol/L.On day 7 of the withdrawal,the patient's liver function improved (ALT 75 U/L,AST 33 U/L,TBil 6.4 μmol/L,and DBil 3.3 μmol/L) and her neutrophil count was 1.60 × 109/L.One week after discharge,the neutrophil count was 1.70 × 109/L;the levels of ALT,AST,TBil,and DBil were 30 U/L,34 U/L,10.0 μmol/L,and 4.2 μmol/L,respectively.